DiaMedica files clinical hold response; Q1 cash $28.7M; Phase 1C confirms DM199 dose safety

DiaMedica Therapeutics Inc.

Company will file complete clinical hold response to FDA this week for ReMEDy2 AIS trial; in-use study supports dose revision to 0.5 µg/kg IV.
Phase 1C SAD study in healthy volunteers affirms revised DM199 IV dose is well-tolerated and achieves therapeutic blood levels.
Cash, cash equivalents and investments $28.7M as of March 31, 2023; working capital $26.9M; cash runway into Q4 2024.
R&D expenses $3.6M in Q1 2023, up 80% YoY, driven by clinical hold studies and team expansion; G&A $1.9M, up 19%.
Post-quarter $0.75M private investment from newly appointed Chief Business Officer; net cash used in ops $5.1M in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DiaMedica Therapeutics Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 15, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the quarter ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-014610

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.